Combination therapy using sympathetic nervous system antagonists and endothelin antagonists
CA 2355411 A1 · Owner: Heaton, Jeremy P.W. · Inventors: Heaton, Jeremy P.W.; Bridge, Suzanne K.; Adams, Michael A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods are provided for preventing or inhibiting adverse cardiovascular effects, associated with administration of a sympathetic nervous system antagonist in a subject, in, which a subject in need thereof is administered a sympathetic nervous system antagonist and, an endothelin antagonist. Methods of treating hypertension in a subject are also provided, in, which a subject in need thereof is administered a sympathetic nervous system antagonist and, an endothelin antagonist. Methods for improving the efficacy of a sympathetic nervous system, antagonist are also provided comprising administering to a subject in need thereof a, sympathetic nervous system antagonist together with an …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 16, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 16, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 16, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.